Furthermore, research by Emma Probst Brandum et al. further revealed that CCR7 antagonists may be beneficial in preventing the recruitment of immune cells to inflamed tissues, thereby preventing autoimmune reactions from worsening in the early stages of diseases such as RA, suggesting that in inflammatory diseases like RA, CCR7 may participate in and promote disease progression, and its expression may be relatively high or at least expressed in certain cell types (such as DCs) [24]. The gene discussed is CCR7; the disease is rheumatoid arthritis.